CHAMPIONS extension: 10-year outcomes in interferon beta-1a-treated patients at high risk for developing multiple sclerosis after a clinically isolated syndrome

被引：0
|
作者：
Putzki, N. [1 ,2 ]
Kinkel, R. P. [3 ]
Dontchev, M. [4 ]
Tanner, J. P. [4 ]
Kollman, C. [4 ]
Simon, J. [5 ]
O'Connor, P. [6 ]
Hyde, R. [7 ]
机构：
[1] Cantonal Hosp, St Gallen, Switzerland
[2] Univ Duisburg Essen, Dept Neurol, Essen, Germany
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Hlth Res Fdn Inc, Jaeb Ctr, Tampa, FL USA
[5] Portland VA Med Ctr, Portland, OR USA
[6] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[7] Biogen Idec Inc, Cambridge, MA USA
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2009年 / 285卷
关键词：
D O I：
10.1016/S0022-510X(09)70475-7
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S119 / S120
页数：2
相关论文
共 50 条
  • [21] Cognitive impairment and structural brain changes in patients with clinically isolated syndrome at high risk for multiple sclerosis
    Hynicova, Eva
    Vyhnalek, Martin
    Kalina, Adam
    Martinkovi, Lukas
    Nikolai, Tomas
    Lisy, Jiri
    Hort, Jakub
    Meluzinova, Eva
    Laczo, Jan
    JOURNAL OF NEUROLOGY, 2017, 264 (03) : 482 - 493
  • [22] Cognitive impairment and structural brain changes in patients with clinically isolated syndrome at high risk for multiple sclerosis
    Eva Hynčicová
    Martin Vyhnálek
    Adam Kalina
    Lukáš Martinkovič
    Tomáš Nikolai
    Jiří Lisý
    Jakub Hort
    Eva Meluzínová
    Jan Laczó
    Journal of Neurology, 2017, 264 : 482 - 493
  • [23] COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS: MODEL UTILIZING FIVE YEAR BENEFIT DATA
    Caloyeras, J. P.
    Harrow, B.
    Wang, C.
    Beckmann, K.
    Knappertz, V
    Pohl, C.
    Miller, J. D.
    Russell, M. W.
    Sandbrink, R.
    Gondek, K.
    VALUE IN HEALTH, 2009, 12 (03) : A14 - A14
  • [24] Intramuscular interferon beta-1a delays conversion to clinically definite multiple sclerosis in patients with a clinically isolated syndrome: subgroup analyses based on new diagnostic criteria
    Kinkel, R. P.
    O'Connor, P. W.
    Kremenchutzky, M.
    MULTIPLE SCLEROSIS, 2006, 12 : S187 - S188
  • [25] AMETYST - Observational Phase IV Study Following the Influence of Intramuscularly Administered Interferon Beta-1a in Patients with Clinically Isolated Syndrome/Clinically Definite Multiple Sclerosis
    Stourac, P.
    Horakova, D.
    Mavrov, I.
    Turcani, P.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2014, 77 (04) : 465 - 472
  • [26] Texture analysis of brain magnetic resonance imaging differs in pediatric clinically isolated syndrome patients at low risk and high risk for developing multiple sclerosis
    Antel, Samson
    Bar-Or, Amit
    Sadovnick, Dessa
    Banwell, Brenda
    Arnold, Douglas L.
    MULTIPLE SCLEROSIS, 2008, 14 : S95 - S95
  • [27] MRI results of a phase III trial of interferon beta-1a treatment in patients at high risk of developing multiple sclerosis
    Simon, JH
    Beck, R
    Jacobs, LD
    Kinkel, RP
    Brownscheidle, CM
    Miller, A
    Murray, TJ
    Simonian, N
    Alam, J
    Slasor, P
    Sandrock, A
    NEUROLOGY, 2000, 54 (12) : 2351 - 2351
  • [28] Risk of Stroke in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon beta-1a (scIFNβ-1a)
    Sabido, Meritxell
    Venkatesh, Saritha
    Aldridge, Julie
    Gillett, Alan
    NEUROLOGY, 2018, 90
  • [29] Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis
    Freedman, Mark S.
    Jack, Dominic
    Murgasova, Zuzana
    Todorovic, Milorad
    Seitzinger, Andrea
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 56
  • [30] Early MRI activity during interferon beta-1a therapy predicts disease activity at 5 years in patients at high risk for developing clinically definite multiple sclerosis
    Kinkel, R. P.
    Pace, A.
    Simon, J.
    O'Connor, P. W.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S129 - S129
12345